Premium
Delivery of paclitaxel and cetuximab by nanodiamond enhances mitotic catastrophe and tumor inhibition in colorectal cancer
Author(s) -
Lin YuWei,
Liao WeiSiang,
Lin Johnson,
Liu KuangKai,
Cheng HsiaoChun,
Wang ChiChing,
Li Yi,
Chen Chinpiao,
Chao JuiI
Publication year - 2016
Publication title -
the faseb journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.709
H-Index - 277
eISSN - 1530-6860
pISSN - 0892-6638
DOI - 10.1096/fasebj.30.1_supplement.1107.6
Subject(s) - mitotic catastrophe , cetuximab , cancer research , paclitaxel , colorectal cancer , apoptosis , mitosis , growth inhibition , cancer cell , cancer , medicine , chemistry , biology , microbiology and biotechnology , biochemistry
Nanomaterials provide the opportunities to improve the efficacies for cancer therapy. Nanodiamond (ND) is a promising carbon nanomaterial developed for novel cancer treatment. Here, we show ND‐carried paclitaxel (PTX), a mitotic blocker, and cetuximab (Cet) (a specific EGFR antibody) that enhances mitotic catastrophe and tumor inhibition in human colorectal cancer (CRC). ND‐PTX induced the mitotic catastrophe and apoptosis in a variety of human CRC cell lines; in contrast, ND alone did not induce cell death. ND‐PTX blocked the mitotic progression, caused abnormal chromosomes separation and subsequently induced the caspase‐3 activation and PARP protein cleavage for apoptosis induction. ND‐PTX inhibited the xenografted human CRC tumors in nude mice. Furthermore, ND‐PTX‐Cet enhanced the cellular uptake ability and apoptosis induction and tumor growth inhibition in the EGFR‐expressed colorectal cancer cells. The mitotic marker of phospho‐histone H3 proteins was highly elicited by ND‐PTX‐Cet in CRC tissues. These results demonstrate that ND is a promising nanocarrier of PTX and Cet for developing novel CRC therapy.